Stat Consult

Vandetanib (Caprelsa)

This slideshow reviews vandetanib (Caprelsa), indicated for symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Table of Contents Slide 4: Dosage and AdministrationSlide 11: Cautions, Effects, and InteractionsSlide 20: What to Tell Your PatientSlide 29: Reference

Blinatumomab (Blincyto)

This slideshow reviews blinatumomab (Blincyto), indicated for Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Table of Contents Slide 4: Dosage and AdministrationSlide 16: Cautions, Effects, and InteractionsSlide 28: What to Tell Your PatientSlide 36: Reference

Bosutinib (Bosulif)

This slideshow reviews bosutinib (Bosulif), indicated for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy. Table of Contents Slide 4: Dosage and AdministrationSlide 11: Cautions, Effects, and InteractionsSlide 18: What to Tell Your PatientSlide 27: Reference

Sorafenib (Nexavar)

This slideshow reviews sorafenib (Nexavar), indicated for the treatment of unresectable hepatocellular carcinoma (HCC), advanced renal cell carcinoma (RCC), and locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment. Table of Contents Slide 4: Dosage and AdministrationSlide 10: Cautions, Effects, and InteractionsSlide 17: What to Tell Your PatientSlide 24: Reference

Rucaparib (Rubraca)

This slideshow reviews rucaparib (Rubraca), indicated for the treatment of deleterious BRCA mutation (germline and/or somatic) associated with advanced ovarian cancer who have been treated with 2 or more chemotherapies. Table of Contents Slide 4: Dosage and AdministrationSlide 10: Cautions, Effects, and InteractionsSlide 17: What to Tell Your PatientSlide 26: Reference

Olaratumab (Lartruvo)

This slideshow reviews olaratumab (Lartruvo), indicated for the treatment of soft tissue sarcoma with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. Table of Contents Slide 4: Dosage and AdministrationSlide 10: Cautions, Effects, and InteractionsSlide 16: What to Tell Your PatientSlide 21:…

Lenvatinib (Lenvima)

This slideshow reviews lenvatinib (Lenvima), indicated for the treatment ofLocally recurrent or metastatic, progressive radioactive iodine-refractory differentiated thyroid cancer or advanced renal cell carcinoma following 1 prior anti-angiogenic therapy. Table of Contents Slide 4: Dosage and AdministrationSlide 15: Cautions, Effects, and InteractionsSlide 25: What to Tell Your PatientSlide 33: Reference

Pembrolizumab (Keytruda)

This slideshow reviews pembrolizumab (Keytruda), indicated for the treatment of unresectable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC), and recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Table of Contents Slide 4: Dosage and AdministrationSlide 12: Cautions, Effects, and InteractionsSlide 19: What to Tell Your PatientSlide 27: Reference

Dexrazoxane (Zinecard)

This slideshow examines dexrazoxane (Zinecard), indicated for the treatment of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer. Table of Contents Slide 4: Dosage and AdministrationSlide 9: Cautions, Effects, and InteractionsSlide 16: What to Tell Your PatientSlide 21: Reference

Crizotinib (Xalkori)

This slideshow examines crizotinib (Xalkori), indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive and metastatic NSCLC whose tumors are ROS1-positive. Table of Contents Slide 4: Dosage and AdministrationSlide 14: Cautions, Effects, and InteractionsSlide 22: What to Tell Your PatientSlide 31: Reference

Next hm-slideshow in Slides